Dr. Paul Nunzio DeSantis

About the Author Dr. Paul Nunzio DeSantis

Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.




Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%25252c-pharm.d

Tekmira/Oncore Merger Represents Substantial Upside

Well, one IPO we were eagerly awaiting is no longer on this year’s docket with Tekmira’s (NASDAQ:TKMR) merger agreement with Oncore announced tonight …

Achillion Pharmaceuticals: Still Bullish, But Taking Profits

Entry: $9.86 10/2/14 Take Profits: $14.

Insuline: Significant Upside, Alternative Diabetes Play With A Population Based Cost-Reduction Platform In Diabetes

Big Picture Thesis: Since Afrezza’s approval MannKind’s (NASDAQ:MNKD) shares have declined more than 50% as enthusiasm for their partnership with Sanofi-Aventis (NYSE:SNY) has …

Achillion: Positioned To Deliver The Last Clinical Stage Nuc To The Highest Bidder

Investment Thesis We expect volatility in the share prices of HCV focused companies leading into this year’s AASLD meeting from November 7th to …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts